Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARAV NASDAQ:CYAD NASDAQ:GDTC NASDAQ:GLPG On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARAVAravive$0.04$0.04$0.04▼$2.46N/AN/AN/AN/ACYADCelyad$0.60$0.67$0.46▼$3.07N/AN/AN/A3,009 shsGDTCCytoMed Therapeutics$2.13-6.4%$1.95$1.20▼$4.05N/A-0.3881,370 shs10,407 shsGLPGGalapagos$31.88-0.4%$31.88$22.36▼$33.86$2.10B0.22315,389 shs76,405 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARAVAravive0.00%0.00%0.00%0.00%0.00%CYADCelyad0.00%0.00%0.00%0.00%0.00%GDTCCytoMed Therapeutics0.00%+18.23%+26.11%+8.61%+51.33%GLPGGalapagos0.00%-4.02%-1.39%+11.18%+6.17%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARAVAravive$0.04$0.04$0.04▼$2.46N/AN/AN/AN/ACYADCelyad$0.60$0.67$0.46▼$3.07N/AN/AN/A3,009 shsGDTCCytoMed Therapeutics$2.13-6.4%$1.95$1.20▼$4.05N/A-0.3881,370 shs10,407 shsGLPGGalapagos$31.88-0.4%$31.88$22.36▼$33.86$2.10B0.22315,389 shs76,405 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARAVAravive0.00%0.00%0.00%0.00%0.00%CYADCelyad0.00%0.00%0.00%0.00%0.00%GDTCCytoMed Therapeutics0.00%+18.23%+26.11%+8.61%+51.33%GLPGGalapagos0.00%-4.02%-1.39%+11.18%+6.17%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARAVAravive 0.00N/AN/AN/ACYADCelyad 0.00N/AN/AN/AGDTCCytoMed Therapeutics 3.00Buy$5.00135.29% UpsideGLPGGalapagos 1.17Strong Sell$26.00-18.44% DownsideCurrent Analyst Ratings BreakdownLatest CYAD, ARAV, GDTC, and GLPG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/5/2025GLPGGalapagosDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold ➝ Sell(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARAVAravive$9.14MN/AN/AN/AN/AN/ACYADCelyad$200KN/AN/AN/A$0.02 per shareN/AGDTCCytoMed Therapeutics$50KN/AN/AN/A$0.61 per shareN/AGLPGGalapagos$275.61M7.62$0.72 per share44.10$47.57 per share0.67Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARAVAravive-$76.32MN/A0.00∞N/AN/AN/AN/AN/ACYADCelyad-$6.30MN/A0.00∞N/AN/AN/AN/AN/AGDTCCytoMed Therapeutics-$1.84MN/A0.00∞N/AN/AN/AN/A9/30/2025 (Estimated)GLPGGalapagos$80.16MN/A0.00N/AN/AN/AN/AN/A10/22/2025 (Estimated)Compare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARAVAraviveN/AN/AN/AN/AN/ACYADCelyadN/AN/AN/AN/AN/AGDTCCytoMed TherapeuticsN/AN/AN/AN/AN/AGLPGGalapagosN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARAVAraviveN/AN/AN/ACYADCelyad1.492.292.14GDTCCytoMed Therapeutics0.059.899.89GLPGGalapagosN/A8.087.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARAVAravive35.80%CYADCelyadN/AGDTCCytoMed Therapeutics0.04%GLPGGalapagos32.46%Insider OwnershipCompanyInsider OwnershipARAVAravive60.40%CYADCelyad0.94%GDTCCytoMed TherapeuticsN/AGLPGGalapagos2.91%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARAVAravive20N/AN/ANo DataCYADCelyad95N/AN/ANot OptionableGDTCCytoMed TherapeuticsN/AN/AN/ANot OptionableGLPGGalapagos1,31065.90 millionN/AOptionableCYAD, ARAV, GDTC, and GLPG HeadlinesRecent News About These CompaniesGalapagos NV (GLPG)’ CAR-T Therapy Hits 97% Response Rate in Lymphoma TrialSeptember 12 at 6:51 PM | finance.yahoo.comGalapagos NV (GLPG)’ CAR-T Therapy Hits 97% Response Rate in Lymphoma TrialSeptember 12 at 6:46 AM | msn.com11 Best Performing Biotech Stocks So Far in 2025September 10, 2025 | insidermonkey.comGalapagos ADR Reaches 80-Plus Relative Strength Rating BenchmarkSeptember 9, 2025 | msn.comGalapagos NV Advances in CAR T Cell Therapy for Non-Hodgkin LymphomaSeptember 7, 2025 | msn.comBVF Inc. IL Sells 115,000 Shares of Galapagos NV $GLPGSeptember 5, 2025 | marketbeat.comOLD Mission Capital LLC Invests $1.89 Million in Galapagos NV $GLPGSeptember 2, 2025 | marketbeat.comFDA Grants RMAT Status to Novel CAR-T GLPG5101 for Mantle Cell LymphomaAugust 13, 2025 | targetedonc.comTGalapagos NV Launches New Subscription Right Plan for ManagementAugust 7, 2025 | tipranks.comGalapagos Creates New Subscription Right PlanAugust 7, 2025 | globenewswire.comGalapagos shares drop 6% as Deutsche Bank cuts rating on strategy concernsAugust 7, 2025 | investing.comGalapagos NV Secures FDA RMAT Designation for GLPG5101August 6, 2025 | tipranks.comGalapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell LymphomaAugust 6, 2025 | globenewswire.comDeutsche Bank downgrades Galapagos to Sell amid ‘too much uncertainty’August 6, 2025 | msn.comGalapagos Appoints New Directors to Strengthen BoardJuly 23, 2025 | tipranks.comGalapagos Bolster Leadership Team with Seasoned Life Sciences Executives to Accelerate Business TransformationJuly 23, 2025 | globenewswire.comGalapagos Welcomes Seasoned Pharmaceutical Executives Dawn Svoronos and Jane Griffiths to Its Board of DirectorsJuly 23, 2025 | globenewswire.comGalapagos Reports Half-Year 2025 Financial Results and Provides Second Quarter Business UpdateJuly 23, 2025 | globenewswire.comGalapagos NV ADR News (GLPG) - Investing.comJuly 9, 2025 | investing.comGalapagos N.V. ADR Advanced Charts | GLPG | Barron'sJune 29, 2025 | barrons.comGalapagos NV ADR Analysis & Opinion (GLPG) - Investing.comJune 28, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCYAD, ARAV, GDTC, and GLPG Company DescriptionsAravive NASDAQ:ARAV$0.04 0.00 (0.00%) As of 09/12/2025Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.Celyad NASDAQ:CYADCelyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.CytoMed Therapeutics NASDAQ:GDTC$2.12 -0.15 (-6.39%) Closing price 03:57 PM EasternExtended Trading$2.12 0.00 (-0.24%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company was incorporated in 2018 and is headquartered in Singapore.Galapagos NASDAQ:GLPG$31.88 -0.14 (-0.44%) Closing price 04:00 PM EasternExtended Trading$31.86 -0.02 (-0.05%) As of 06:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Adobe’s Rebound Has Room to Run: 25% Upside by Year-End Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
